This episode of the podcast "This Week in Virology" features an expert discussion with David Barton, Brian Kemp, and Olve Peersen on the critical role of RNA recombination in enteroviruses and its significant impact on the global poliovirus eradication strategy. The conversation delves into the molecular mechanics of the poliovirus RNA polymerase, which facilitates a form of "sexual" replication through recombination. This process allows the virus to exchange genetic material with related enteroviruses, purging deleterious mutations and maintaining fitness. A key focus is the failure of the novel oral polio vaccine (nOPV2), which, despite being engineered for stability, still reverted to a virulent form in the field. The experts explain that the vaccine virus recombined with other circulating enterovirus C strains, surgically replacing its attenuated segments with functional ones. This outcome highlights the immense challenge of out-engineering viral evolution, especially under the intense selective pressure of the human gut. The discussion concludes by questioning the feasibility of eradication with current live attenuated vaccines and exploring the need for new, innovative vaccine technologies.
Poliovirus, Recombination, and the Hurdles to Eradication
21:23 The Poliovirus Polymerase: A Molecular Machine: Guest Olve Peersen describes the structure of the poliovirus RNA-dependent RNA polymerase using a "right-hand" analogy (thumb, fingers, palm) to explain how it functions as a molecular machine to copy the viral genome.
27:31 A Unique Mechanism of Action: Unlike cellular polymerases, viral polymerases are unique in that the incoming nucleotide binds first, which then causes the active site to form around it. This mechanism allows for rapid evolution of replication speed and fidelity.
33:58 RNA Recombination as Viral "Sex": The experts explain that RNA recombination acts as a form of sexual replication for viruses like polio. By co-infecting a cell, two different viruses can swap genetic segments, creating chimeric progeny. This process is crucial for viral fitness, as it allows the virus to purge harmful mutations and avoid "error catastrophe."
38:29 Recombination is Relatively Efficient: Using a lab-based assay, researchers estimate that recombination occurs in about 0.1% to 1% of replication cycles. While seemingly low, this is efficient enough to have a major impact on viral evolution in a host.
44:46 Predicting Recombination Partners: Polioviruses do not recombine randomly with any virus. They belong to specific "recombination groups" (polio is in enterovirus C, group 4) where the polymerases are at least 94% identical at the amino acid level. They preferentially swap genes with members of their own group.
57:33 Why the New Polio Vaccine (nOPV2) Failed: The novel oral polio vaccine (nOPV2) was engineered to be highly stable and resistant to reversion. However, it still caused outbreaks because it recombined with other circulating enterovirus C strains. The intense selective pressure in the human gut drove the virus to overcome the engineered safeguards through a double recombination event, something not observed in less-competitive lab experiments.
1:04:14 A Phenotypic, Not Genotypic, Reversion: The resulting virulent virus is not a true "reversion" where the original mutations reappeared. Instead, it is a recombinant virus that has surgically replaced its debilitated genetic segments with fully functional ones from a co-infecting virus, leading to a "phenotypic reversion" (a return to virulence).
1:06:18 A Potential Design Flaw: A key conceptual weakness of nOPV2 may have been attenuating the non-capsid genes. Since these replication genes are readily swapped out via recombination, a more robust strategy might have been to introduce attenuating mutations into the capsid genes, which are the ultimate target of eradication efforts.
1:22:11 Is Polio Eradication Achievable?: The guests express skepticism about eradicating polio using any live attenuated vaccine that can be transmitted, as this continuously seeds the potential for new outbreaks. They argue that the focus should be on disease control and that true eradication will require new, innovative vaccines that are nucleic-acid-free, orally deliverable, and can induce durable mucosal immunity.
1:30:58 The Ecological Risk of Eradication: A final concern is that successfully eradicating the three poliovirus serotypes could create an "ecological vacuum" in the human gut. This niche could potentially be filled by another enterovirus that evolves to cause paralysis, creating a new public health threat.